Clinical study on Bushen Huoxue Decoction in the treatment of peripheral neuropathy of multiple myeloma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037415

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-11-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Experimental group:Bushen Huoxue Decoction Combined with Mecobalamin

control:Mecobalamin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Multiple myeloma peripheral neuropathy was diagnosed; 2) Aged between 25 and 85 years old; 3) Conscious and willing to accept the trial treatment.

Exclusion criteria

Exclusion criteria: 1) Those who do not meet the inclusion criteria; 2) Those who are allergic to the test drug; 3) Patients with important organ dysfunction and mental disorders; 4) Participants in other clinical drug trials; 5) Those who suffer from mental illness or mental disorder and cannot be controlled.

Design outcomes

Primary

Measure	Time frame
Curative effect of TCM Syndrome;M protein;Neurological symptom score;Neurological sign score;nerve conduction velocity;	—

Countries

China

Contacts

Public ContactChen Yirong

Shanghai municipal Hospital of Traditional Chinese Medicine

272378786@qq.com+86 13501835252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026